Panitumumab (ABX-EGF) 是一种全人源 IgG2 抗 EGFR 单克隆抗体，具有抗肿瘤活性。Panitumumab 抑制肿瘤细胞增殖、存活和血管生成。Panitumumab 可用于癌症研究，例如结肠癌。
| Cas No. | 339177-26-3 |
| 别名 | ABX-EGF |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFRmonoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer[1][2][4]. Panitumumab (2 nM-2 μM, 3 h) inhibits ligand-dependent autophosphorylation in EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells[3].
Panitumumab (0-200 μg/mL, 48 h) inhibits the proliferation of DLD-1 cells[4].
Panitumumab (80 μg/mL, 24 h) increase beclin-1 (a marker of autophagy) levels in Caco-2 cells and DLD-1 cells[4].
Western Blot Analysis[3] | Cell Line: | EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells | | Concentration: | 2, 20, 200, 2000 nM | | Incubation Time: | 3 h | | Result: | Inhibited ligand-induced autophosphorylation of EGFR. |
Panitumumab (25, 100, or 500 μg/mouse, i.p., twice a week) inhibits tumor growth in NCI-H1975 and NCI-H1650 xenografts, compared with control (P< 0.0003)[1]. | Animal Model: | NCI-H1975 and NCI-H1650 xenografts[3] | | Dosage: | 25, 100, or 500 μg/mouse | | Administration: | Intraperitoneal injection (i.p.), twice a week | | Result: | Inhibited ligand-induced EGFR phosphorylation, tumor growth, and markers of proliferation.
Decreased Ki-67 and phospho- mitogen-activated protein kinase (pMAPK) staining in both xenografts. |
|
